Why is homocysteine elevated in renal failure and what can be expected from homocysteine-lowering?

Nephrology Dialysis Transplantation

Volumn 21, Issue 5, 2006, Pages 1161-1166

  van Guldener, Coen ^a  

^a AMPHIA HOSPITAL   (Netherlands)

Author keywords

Folic acid; Homocysteine; Sulphur amino acids

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PLACEBO; PYRIDOXINE; SULFUR AMINO ACID;

AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; BLOOD ANALYSIS; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG DOSE REGIMEN; DRUG MEGADOSE; EDITORIAL; ENDOTHELIAL DYSFUNCTION; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; HYPERHOMOCYSTEINEMIA; KIDNEY BLOOD FLOW; KIDNEY CLEARANCE; KIDNEY FAILURE; KIDNEY METABOLISM; LOW DRUG DOSE; PATHOGENESIS; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN METHYLATION; PROTEIN MODIFICATION; PROTEIN TRANSPORT; URINARY EXCRETION; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VASODILATATION;

FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; PROGNOSIS; RENAL DIALYSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VITAMIN B 6;

EID: 33646186618     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl044     Document Type: Editorial

References (43)

1. Ducloux D, Motte G, Challier B, Gibey R, Chalopin JM. Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: A prospective study. J Am Soc Nephrol 2000; 11: 134-137
2. Mallamaci F, Zoccali C, Tripepi G et al. Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int 2002; 61: 609-614
3. Winkelmayer WC, Kramar R, Curhan GC et al. Fasting plasma total homocysteine levels and mortality and allograft loss in kidney transplant recipients: A prospective study. J Am Soc Nephrol 2005; 16: 255-260
4. Suliman ME, Qureshi R, Barany P et al. Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. Kidney Int 2000; 57: 1727-1735
5. Kalantar-Zadeh K, Block G, Humphreys MH, McAllister CJ, Kopple JD. A low, rather than a high, total plasma homocysteine is an indicator of poor outcome in hemodialysis patients. J Am Soc Nephrol 2004; 15: 442-453
6. Wrone EM, Hornberger JM, Zehnder JL, McCann LM, Coplon NS, Fortmann SP. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol 2004; 15: 420-426
7. Suliman ME, Barany P, Kalantar-Zadeh K, Lindholm B, Stenvinkel P. Homocysteine in uraemia - a puzzling and conflicting story. Nephrol Dial Transplant 2005; 20: 16-21
8. Wollesen F, Brattstrom L, Refsum H, Ueland PM, Berglund L, Berne C. Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus. Kidney Int 1999; 55: 1028-1035
9. Veldman BA, Vervoort G, Blom H, Smits P. Reduced plasma total homocysteine concentrations in Type 1 diabetes mellitus is determined by increased renal clearance. Diabet Med 2005; 22: 301-305
10. Samuelsson O, Lee DM, Attman PO et al. The plasma levels of homocysteine are elevated in moderate renal insuficiency but do not predict the rate of progression. Nephron 1999; 82: 306-311
11. Sarnak MJ, Wang SR, Beck GJ et al. Homocysteine, cysteine, and B vitamins as predictors of kidney disease progression. Am J Kidney Dis 2002; 40: 932-939
12. Hovind P, Tarnow L, Rossing P et al. Progression of diabetic nephropathy: Role of plasma homocysteine and plasminogen activator inhibitor-1. Am J Kidney Dis 2001; 38: 1376-1380
13. Ninomiya T, Kiyohara Y, Kubo M et al. Hyperhomocysteinemia and the development of chronic kidney disease in a general population: The Hisayama study. Am J Kidney Dis 2004; 44: 437-445
14. Refsum H, Helland S, Ueland PM. Radioenzymic determination of homocysteine in plasma and urine. Clin Chem 1985; 31: 624-628
15. House JD, Brosnan ME, Brosnan JT. Renal uptake and excretion of homocysteine in rats with acute hyperhomocysteinemia. Kidney Int 1998; 54: 1601-1607
16. van Guldener C, Donker AJ, Jakobs C, Teerlink T, de Meer K, Stehouwer CD. No net renal extraction of homocysteine in fasting humans. Kidney Int 1998; 54: 166-169
17. Garibotto G, Sofia A, Saffioti S et al. Interorgan exchange of aminothiols in humans. Am J Physiol Endocrinol Metab 2003; 284: E757-E763
18. Tizianello A, De Ferrari G, Garibotto G, Gurreri G, Robaudo C. Renal metabolism of amino acids and ammonia in subjects with normal renal function and in patients with chronic renal insufficiency. J Clin Invest 1980; 65: 1162-1173
19. Laidlaw SA, Berg RL, Kopple JD, Naito H, Walker WG, Walser M. Patterns of fasting plasma amino acid levels in chronic renal insufficiency: results from the feasibility phase of the modification of diet in renal disease study. Am J Kidney Dis 1994; 23: 504-513
20. Allen RH, Stabler SP, Lindenbaum J. Serum betaine, N,N-dimethylglycine and N-methylglycine levels in patients with cobalamin and folate deficiency and related inborn errors of metabolism. Metabolism 1993; 42: 1448-1460
21. Loehrer FMT, Angst CP, Brunner FP, Haefeli WE, Fowler B. Evidence for disturbed S-adenosylmethionine: S-adenosylhomocysteine ratio in patients with end-stage renal failure: A cause for disturbed methylation reactions? Nephrol Dial Transplant 1998; 13: 656-661
22. Herrmann W, Schorr H, Geisel J, Riegel W. Homocysteine, cystathionine, methylmalonic acid and B-vitamins in patients with renal disease. Clin Chem Lab Med 2001; 39: 739-746
23. Suliman ME, Anderstam B, Lindholm B, Bergstrom J. Total, free, and protein-bound sulphur amino acids in uraemic patients. Nephrol Dial Transplant 1997; 12: 2332-2338
24. Nakanishi T, Otaki Y, Hasuike Y et al. Association of hyperhomocysteinemia with plasma sulphate and urine excretion in patients with progressive renal disease. Am J Kidney Dis 2002; 40: 909-915
25. Ducloux D, Aboubakr A, Motte G et al. Hyperhomocysteinaemia therapy in haemodialysis patients: Folinic versus folic acid in combination with vitamin B6 and B12. Nephrol Dial Transplant 2002; 17: 865-870
26. Ghandour H, Bagley PJ, Shemin D et al. Distribution of plasma folate forms in hemodialysis patients receiving high daily doses of 1-folinic or folic acid. Kidney Int 2002; 62: 2246-2249
27. Massy ZA. Reversal of hyperhomocyst(e)inaemia in chronic renal failure - Is folic or folinic acid the answer? Nephrol Dial Transplant 1999; 14: 2810-2812
28. Suliman ME, Divino Filho JC, Barany P, Anderstam B, Lindholm B, Bergstrom J. Effects of high-dose folic acid and pyridoxine on plasma and erythrocyte sulfur amino acids in hemodialysis patients. J Am Soc Nephrol 1999; 10: 1287-1296
29. van Guldener C, Kulik W, Berger R et al. Homocysteine and methionine metabolism in ESRD: A stable isotope study. Kidney Int 1999; 56: 1064-1071
30. Stam F, van Guldener C, ter Wee PM et al. Homocysteine clearance and methylation flux rates in health and end-stage renal disease: association with S-adenosylhomocysteine. Am J Physiol Renal Physiol 2004; 287: F215-F223
31. Stam F, van Guldener C, ter Wee PM, Jakobs C, de Meer K, Stehouwer CD. Effect of folic acid on methionine and homocysteine metabolism in end-stage renal disease. Kidney Int 2005; 67: 259-264
32. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998; 338: 1042-1050
33. van Guldener C, Lambert J, Janssen MJ, Donker AJ, Stehouwer CD. Endothelium-dependent vasodilatation and distensibility of large arteries in chronic haemodialysis patients. Nephrol Dial Transplant 1997; 12 [Suppl 2]: 14-18
34. van Guldener C, Janssen MJ, Lambert J, Steyn M, Donker AJ, Stehouwer CD. Endothelium-dependent vasodilatation is impaired in peritoneal dialysis patients. Nephrol Dial Transplant 1998; 13: 1782-1786
35. Thambyrajah J, Landray MJ, McGlynn FJ, Jones HJ, Wheeler DC, Townend JN. Does folic acid decrease plasma homocysteine and improve endothelial function in patients with predialysis renal failure? Circulation 2000; 102: 871-875
36. Bayés B, Cruz Pastor M, Bonal J et al. Homocysteine, C-reactive protein, lipid peroxidation and mortality in haemodialysis patients. Nephrol Dial Transplant 2003; 18: 106-112
37. van Guldener C, Janssen MJ, Lambert J et al. No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinaemia in haemodialysis patients. Nephrol Dial Transplant 1998; 13: 106-112
38. van Guldener C, Janssen MJ, Lambert J, ter Wee PM, Donker AJ, Stehouwer CD. Folic acid treatment of hyperhomocysteinemia in peritoneal dialysis patients: No change in endothelial function after long-term therapy. Perit Dial Int 1998; 18: 282-289
39. Dierkes J, Domrose U, Ambrosch A, Bosselmann HP, Neumann KH, Luley C. Response of hyperhomocysteinemia to folic acid supplementation in patients with end-stage renal disease. Clin Nephrol 1999; 51: 108-115
40. van Guldener C, Lambert J, ter Wee PM, Donker AJ, Stehouwer CD. Carotid artery stiffness in patients with endstage renal disease: No effect of long-term homocysteine-lowering therapy. Clin Nephrol 2000; 53: 33-41
41. Ingrosso D, Cimmioni A, Perna AF et al. Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinaemia in patients with uraemia. Lancet 2003; 361: 1693-1699
42. van Guldener C, Stam F, Stehouwer CD. Hyperhomocysteinaemia in chronic kidney disease: Focus on transmethylation. Clin Chem Lab Med 2005; 43: 1026-1031
43. Jamison RL, Hartigan P, Gaziano JM et al. Design and statistical issues in the homocysteinemia in kidney and end stage renal disease (HOST) study. Clin Trials 2004; 1: 451-460